ATS 2020 Advance Program

controversial treatments for COPD including stem cell therapy and medical marijuana; • learn new concepts from large cohort studies that could be applied to the re-classification of COPD and understand the potential benefits and limitations of proceeding with disease reclassification. Available guideline based therapy for COPD is limited in ability to restore quality of life, prevent exacerbations, slow decline in lung function or prolong life. Given these limitations, clinicians are attempting new approaches to treatment and patients are willing to attempt therapies with limited evidence base. Further, recent cohort studies have exposed limitations in our current classification scheme for COPD, and there is speculation that reclassification of the disease will fuel the field to move forward. The session will have experts involved with development of several emerging and controversial therapies in COPD to assess the evidence base for existing and future use to treat our patients with COPD. Chairing: F.C. Sciurba, MD, Pittsburgh, PA J.M. Bon, MD, MS, ATSF, Pittsburgh, PA B.J. Make, MD, Denver, CO Speakers and Talks to be Announced CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE D83 TELOMERES IN INTERSTITIAL LUNG DISEASE AND LUNG TRANSPLANTATION Assemblies on Clinical Problems; Respiratory Cell and Molecular Biology 1:00 p.m. - 3:00 p.m. Target Audience Pulmonologists who diagnosis and treat patients with interstitial lung disease; transplant pulmonologists, surgeons, and associated health care professionals. Objectives At the conclusion of this session, the participant will be able to: • identify patients with ILD who should be screened for short telomeres and pathogenic variants in telomere biology genes, including understanding research and commercially available telomere length testing; • refer patients with telomere biology-related ILD for transplant evaluation earlier and to define new strategies to manage the care of this population, including novel therapies; • improve post-transplant management of individuals with telomere biology-related ILD, including the identification of specific protocols for this population. Common single nucleotide polymorphisms and rare pathogenic germline variants in telomere biology genes are associated with very short telomeres resulting in organ dysfunction, including interstitial lung disease (ILD). This symposium will focus on the diagnosis and management of patients with telomere biology-related ILD, including lung transplantation. Topics will cover translational research on the detection and pathophysiology of telomere biology disorders including pulmonary and extra-pulmonary disease manifestations; screening and management of individuals with telomere-related ILD; patient/family perspectives on living with short telomeres with or without ILD; novel approches in this population; and management of lung transplant candidates and recipients with telomere biology-related ILD. Chairing: S.Y. El-Chemaly, MD, MPH, Boston, MA M. Armanios, MD, Baltimore, MD 1:00 Detection and Clinical Manifestations of Short Telomeres S. Savage, MD, Rockville, MD 1:20 Short Telomeres and Interstitial Lung Disease: Screening and Trajectories C. Newton, MD, Dallas, TX 1:40 Living With Short Telomeres L. Stevens, BA, Philadelphia, PA 2:00 Therapies in Pre-Clinical Models of Telomere-Related Disease M. Blasco, PhD, Madrid, Spain ATS 2020 • Philadelphia, PA WEDNESDAY • MAY 20 141